Cytodyn Inc (CYDY)

[ohm20]

One has to wonder of the standard of care they were comparing with was hydroxychloroquine and azithromycin which would be more likely to increase deaths. The "results" from Gilead are wholly untrustworthy.

Raymond James analyst Steven Seedhouse said Gilead has failed to demonstrate a mortality benefit in three gold-standard clinical trials, and is using the comparative analysis to “approximate” a more rigorous finding. He called the results confusing and said it’s unclear whether the company will be able to confirm the results in a new, properly designed and definitive trial. Others agreed.

“This type of analysis falls well short of the gold standard of a randomized clinical study, and is likely to be misinterpreted as proof that remdesivir improves survival,” Bloomberg Intelligence analysts Marc Engelsgjerd and Jenna Li wrote in a note.

https://www.bloomberg.com/news/articles/2020-07-10/gilead-s-remdesivir-linked-to-62-reduction-in-mortality-risk